Donaldson Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: August-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
The leadership transition from Tod Carpenter to Richard Lewis preserves continuity but requires the board to distinguish mentorship from operational interference. We see this as the central issue in control and governance because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.Public shareholders own Donaldson, with new chief executive Richard Lewis operating under board chair and former chief executive Tod Carpenter. Richard Lewis leads the enterprise and Tod Carpenter provides board or owner oversight, so formal percentages must be read beside board independence, voting rights and contractual authority. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: equipment cycles, customer concentration, raw-material costs, tariffs, currency, life-sciences integration and acquisition goodwill can weaken cash returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $10.85 billion, Donaldson carries a quality premium that assumes durable replacement demand and improving life-sciences returns. A governance premium is earned only when independent oversight reduces agency risk and protects capital through a full cycle. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would tie executive rewards to per-share value, balance-sheet resilience and clearly measured strategic outcomes. We would protect core filtration research while requiring the life-sciences portfolio to meet explicit organic-growth and cash-return milestones. Our view is that Donaldson deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Large passive holders support stability, while active quality investors can press for evidence that acquired life-sciences assets earn their cost of capital. We see this as the central issue in shareholder composition and capital-market behavior because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The institutional register lists The Vanguard Group, BlackRock, State Street, Kayne Anderson Rudnick Investment Management at 10.8%, 9.2%, 4.1%, 3.5%. These stakes influence elections, liquidity and engagement, but they do not guarantee a common view on strategy or risk. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: equipment cycles, customer concentration, raw-material costs, tariffs, currency, life-sciences integration and acquisition goodwill can weaken cash returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $10.85 billion, Donaldson carries a quality premium that assumes durable replacement demand and improving life-sciences returns. Stable institutions can reduce financing uncertainty, but concentration cannot substitute for durable operating results or engaged directors. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We expect major holders to press for transparent capital priorities, credible downside planning and disciplined compensation. We would protect core filtration research while requiring the life-sciences portfolio to meet explicit organic-growth and cash-return milestones. Our view is that Donaldson deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Donaldson | Corporate brand | Filtration products and systems |
| BOFA International | Subsidiary brand | Fume extraction |
| Univercells Technologies | Subsidiary brand | Bioprocessing equipment |
| Solaris Biotechnology | Subsidiary brand | Bioreactors and fermenters |
| Isolere Bio | Subsidiary brand | Biologic purification |
| Purilogics | Subsidiary brand | Membrane chromatography |
| Medica | Subsidiary brand | Clinical analyzer products |
| Facet | Subsidiary brand | Aviation and industrial filtration |
Portfolio Analysis
The Donaldson master brand anchors recurring replacement demand, while specialist life-sciences names need autonomy to retain technical credibility. We see this as the central issue in brand and portfolio strategy because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The portfolio includes Donaldson, BOFA International, Univercells Technologies, Solaris Biotechnology, Isolere Bio, Purilogics, Medica and Facet. Each identity needs a defined customer promise and economic role, with shared capabilities producing measurable benefits instead of administrative complexity. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: equipment cycles, customer concentration, raw-material costs, tariffs, currency, life-sciences integration and acquisition goodwill can weaken cash returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $10.85 billion, Donaldson carries a quality premium that assumes durable replacement demand and improving life-sciences returns. A portfolio premium requires evidence that customer trust, technical know-how or distribution produces stronger retention and margins. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would invest behind identities with the strongest incremental returns and simplify offerings that do not reinforce customer advantage. We would protect core filtration research while requiring the life-sciences portfolio to meet explicit organic-growth and cash-return milestones. Our view is that Donaldson deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Donaldson ★ | N/A | $3.89B FY2026 | Global filtration and process-technology supplier |
| Parker Hannifin | N/A | $20B FY2026 | Diversified motion and filtration supplier |
| Atmus Filtration Technologies | N/A | $2B FY2025 | Engine and industrial filtration competitor |
| MANN HUMMEL | N/A | N/A | Global filtration systems competitor |
| Danaher | N/A | $24B FY2025 | Life-sciences process technology competitor |
Competitive Analysis
Installed equipment, engineering qualification and replacement channels create defensibility, though Parker and Atmus remain formidable in core filtration. We see this as the central issue in competitive position and valuation because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The current performance base is fiscal 2026 sales of $3.886 billion and adjusted earnings of $3.98 per share from 15000 employees. We test competitive strength through pricing, retention, market share, unit economics and return on invested capital instead of broad claims about addressable markets. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: equipment cycles, customer concentration, raw-material costs, tariffs, currency, life-sciences integration and acquisition goodwill can weaken cash returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $10.85 billion, Donaldson carries a quality premium that assumes durable replacement demand and improving life-sciences returns. A competitive premium should follow sustainable cash economics and reinvestment opportunity, not one favorable period or a temporary shortage. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would track leading indicators of pricing power and retention before assuming any cyclical improvement is permanent. We would protect core filtration research while requiring the life-sciences portfolio to meet explicit organic-growth and cash-return milestones. Our view is that Donaldson deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Facet | $72M | 2026 | Expanded aviation and industrial filtration |
| Medica | $24M | 2024 | Added clinical analyzer technology |
| Isolere Bio | $62M | 2023 | Added biologic purification |
| Purilogics | $20M | 2022 | Added membrane chromatography |
| Univercells Technologies | $163M | 2021 | Expanded bioprocessing |
| BOFA International | $99M | 2018 | Added fume extraction |
Acquisitions Analysis
A sequence of smaller life-sciences deals limits single-deal risk but can still accumulate integration cost and underperforming goodwill. We see this as the central issue in acquisition discipline and integration because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The transaction record matters because management balances factory and research investment, dividends, repurchases and bolt-on acquisitions across core filtration and life sciences. We expect post-deal scorecards to compare promised economics with retention, margins, cash conversion and financing costs. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: equipment cycles, customer concentration, raw-material costs, tariffs, currency, life-sciences integration and acquisition goodwill can weaken cash returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $10.85 billion, Donaldson carries a quality premium that assumes durable replacement demand and improving life-sciences returns. Deal-driven growth warrants a premium only when acquired cash flows exceed financing, integration and opportunity costs under conservative assumptions. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would require a conservative base case, an explicit failure case and a formal post-close review before approving another material transaction. We would protect core filtration research while requiring the life-sciences portfolio to meet explicit organic-growth and cash-return milestones. Our view is that Donaldson deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Donaldson has avoided a transformative merger, making disciplined bolt-ons and internal reinvestment the main drivers of structural change. We see this as the central issue in merger, spinoff and structural history because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.Donaldson has remained independent and expanded through focused purchases rather than a defining merger. Recent life-sciences acquisitions created a new growth platform beside the mature mobile and industrial filtration franchises. The 2026 Facet purchase reinforced core filtration exposure and did not alter public ownership. Today's segments, leverage, ownership rights and strategic choices are direct consequences of those structural decisions. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: equipment cycles, customer concentration, raw-material costs, tariffs, currency, life-sciences integration and acquisition goodwill can weaken cash returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $10.85 billion, Donaldson carries a quality premium that assumes durable replacement demand and improving life-sciences returns. Structural change creates value only when accountability, focus or cash generation improves after tax, financing and integration costs. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would support another structural move only if quantified benefits exceed integration cost, leverage and lost flexibility. We would protect core filtration research while requiring the life-sciences portfolio to meet explicit organic-growth and cash-return milestones. Our view is that Donaldson deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Ownership History
Ownership History Analysis
Ownership moved from the Donaldson family to dispersed institutions without abandoning the engineering and replacement-economics culture. We see this as the central issue in ownership and strategic evolution because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The defining arc is a founder-led filtration innovator that became a global public compounder and added life-sciences technologies through a sequence of targeted deals. We assign heritage value only when its best operating lessons remain embedded in incentives, succession and capital discipline. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: equipment cycles, customer concentration, raw-material costs, tariffs, currency, life-sciences integration and acquisition goodwill can weaken cash returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $10.85 billion, Donaldson carries a quality premium that assumes durable replacement demand and improving life-sciences returns. Historical success informs judgment but cannot be capitalized indefinitely when leadership, technology or industry structure changes. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would preserve capabilities that created the franchise while discarding legacy practices that no longer earn adequate returns. We would protect core filtration research while requiring the life-sciences portfolio to meet explicit organic-growth and cash-return milestones. Our view is that Donaldson deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Ownership Explained
Donaldson operates under this ownership structure: Public shareholders own Donaldson, with new chief executive Richard Lewis operating under board chair and former chief executive Tod Carpenter. Richard Lewis leads the enterprise and Tod Carpenter provides board or owner oversight. We treat voting authority, board composition and transaction status as more informative than a shareholder list alone because they determine who can change strategy, approve investments and set risk tolerance.The operating model is a global filtration leader serving engines, industrial processes and a developing life-sciences technology portfolio. Important commercial identities include Donaldson, BOFA International, Univercells Technologies, Solaris Biotechnology, Isolere Bio, Purilogics, Medica and Facet. We see value when these businesses share technology, distribution, procurement or customer insight without weakening local accountability. Portfolio breadth deserves a premium only when common ownership improves retention, margins and reinvestment returns.The latest annual record includes fiscal 2026 sales of $3.886 billion and adjusted earnings of $3.98 per share from 15000 employees. We use the annual period as the clean scale reference and incorporate current 2026 developments when they alter control, governance or earnings power. Interim results can be distorted by seasonality, transaction timing, launch costs, restructuring charges or volatile end markets.Management balances factory and research investment, dividends, repurchases and bolt-on acquisitions across core filtration and life sciences. Our view is that capital allocation is the practical expression of ownership. Management and directors should compare each acquisition, repurchase, development program or restructuring decision with debt reduction and retained liquidity, then report whether actual returns matched the original underwriting.
Ownership shapes disclosure, financing flexibility and accountability at Donaldson. Public shareholders own Donaldson, with new chief executive Richard Lewis operating under board chair and former chief executive Tod Carpenter. We expect the controlling parties and directors to convert authority into durable per-share value rather than treating revenue growth, asset count or transaction volume as ends in themselves.The principal downside exposures are equipment cycles, customer concentration, raw-material costs, tariffs, currency, life-sciences integration and acquisition goodwill can weaken cash returns. We would monitor leading operating indicators that reveal whether the franchise is strengthening before reported earnings fully show the change. Balance-sheet resilience belongs inside ownership analysis because it preserves strategic choice when demand, regulation or capital markets become less favorable.At an August 2026 equity value of $10.85 billion, Donaldson carries a quality premium that assumes durable replacement demand and improving life-sciences returns. That benchmark raises the hurdle for new investment and makes scenario discipline essential. We would compare management's implied expectations with conservative cash returns after financing, integration, stock compensation and restructuring costs instead of relying on adjusted profit alone.We would protect core filtration research while requiring the life-sciences portfolio to meet explicit organic-growth and cash-return milestones. This discipline affects investors, employees, customers, suppliers and creditors because it determines service continuity, employment capacity and financial resilience. We see high-quality ownership only when authority produces transparent decisions, measurable accountability and repeatable cash economics.